Paolo Tarantino, Research Fellow at Dana-Farber Cancer Institute, shared on X about a recent paper by Marko Velimirovic and Jame Abraham published in JCO Oncology Practice:
“Wonderful editorial by Marko Velimirovic and Jame Abraham accompanying our JCO Oncology Practice review on the evolution of HER2 testing in oncology.
Recommend reading to anyone interested in a recap of the epic journey of HER2 as a biomarker over the past 30 years.”
Title: Human Epidermal Growth Factor Receptor 2 Positivity a Moving Target in the Era of Antibody-Drug Conjugates
Journal: JCO Oncology Practice
Authors: Marko Velimirovic, Jame Abraham
More posts featuring Paolo Tarantino on OncoDaily.